In 2015, the World Health Organization (WHO) adopted its ambitious Global Technical Strategy for Malaria (GTS) for 2030: eliminate malaria in 35 countries, reduce malaria incidence and deaths by 90% and prevent resurgence in malaria-free countries.
Where it stands: Significant progress has been made, but malaria remains a major threat — killing one child every two minutes — and is experiencing a resurgence. To meet the GTS targets, current funding will have to more than double to $6.5 billion by 2020.
The largest pharmaceutical companies donated almost twice as much money to patient advocacy groups in 2015 as they spent on federal lobbying, according to a Kaiser Health News investigation.
The big picture: Critics say drug company money could skew the views and priorities of patient groups, many of which have been silent on rising drug prices.
